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RESEARCH
Microbubble-mediated delivery of human 
adenoviruses does not elicit innate and adaptive 
immunity response in an immunocompetent 
mouse model of prostate cancer
Flavia De Carlo1,2,3, Litty Thomas1,2,3, Bell Brooke1,2,3, Elliot T. Varney4, Rounak Nande5, Olivia Boskovic5, 
Gailen D. Marshall6, Pier Paolo Claudio1,2,3,7*  and Candace M. Howard4*
Abstract 
Background: Gene transfer to malignant sites using human adenoviruses (hAds) has been limited because of their 
immunogenic nature and host specificity. Murine cells often lack some of the receptors needed for hAds attachment, 
thus murine cells are generally non-permissive for human adenoviral infection and replication, which limits transla-
tional studies.
Methods: We have developed a gene transfer method that uses a combination of lipid-encapsulated perfluoro-
carbon microbubbles and ultrasound to protect and deliver hAds to a target tissue, bypassing the requirement of 
specific receptors.
Results: In an in vitro model, we showed that murine TRAMP-C2 and human DU145 prostate cancer cells display a 
comparable expression pattern of receptors involved in hAds adhesion and internalization. We also demonstrated 
that murine and human cells showed a dose-dependent increase in the percentage of cells transduced by hAd-GFP 
(green fluorescent protein) after 24 h and that GFP transgene was efficiently expressed at 48 and 72 h post-trans-
duction. To assess if our image-guided delivery system could effectively protect the hAds from the immune system 
in vivo, we injected healthy immunocompetent mice (C57BL/6) or mice bearing a syngeneic prostate tumor (TRAMP-
C2) with hAd-GFP/MB complexes. Notably, we did not observe activation of innate (TNF-α and IL-6 cytokines), or 
adaptive immune response (neutralizing antibodies, INF-γ+  CD8+ T cells).
Conclusions: This study brings us a step closer to demonstrating the feasibility of murine cancer models to investi-
gate the clinical translation of image guided site-specific adenoviral gene therapy mediated by ultrasound-targeted 
microbubble destruction.
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Background
Human adenoviruses (hAds) are highly effective gene 
transfer agents that can introduce different types of 
genetic materials into cancer cells, including tumor 
suppressor genes [1]. Taxonomically grouped into the 
Adenoviridae family, adenoviruses are known to infect a 
wide variety of species [2]. Human adenoviruses are non-
enveloped, icosahedral viruses, approximately 90  nm in 
diameter with a fiber complex known as knob domain 
that binds to the Coxsackie and Adenovirus Receptor 
(CAR), thus mediating cell tropism [3–5]. Interaction of 
adenoviral penton proteins with surface integrins such as 
αVβ3 and αVβ5 assists in the internalization of the virus; 
however, horizontal gene transfer of adenoviruses is often 
difficult due to the strict host specificity demonstrated by 
the viruses [6]. Generally, murine cells lack some of the 
receptors needed for hAd infection, such as CAR, thus 
making them generally non-permissive for hAd infection 
and replication. However, a very low level of hAd infec-
tion and replication has been described in some mouse 
cells [7, 8].
Human adenoviruses serotypes 2 and 5, classified under 
species type C, have shown promising results in treat-
ing locally advanced cancers, but these adenoviruses are 
highly immunogenic triggering both innate and adaptive 
immune responses [3, 4]. The innate immune response is 
elicited in the professional antigen presenting cells (APC) 
by hAds through the myeloid differentiating factor 88 
(MyD88)/Toll-like receptor (TLR)-9 dependent or inde-
pendent pathways resulting in the up-regulation of type 
I interferons (IFNs) and inflammatory cytokines such 
as TNF-α, IL-6 and IL-12 [9, 10]. Complement, another 
key component of the innate immunity, has an important 
role in the opsonization and clearance of adenoviruses. 
Complement activation can occur via direct binding of 
adenovirus with C3-derived fragments or through neu-
tralizing antibodies produced after a previous immuni-
zation [11]. Viral exposure leads to innate and adaptive 
immune system interaction resulting in the differentia-
tion of B cells into antibody-secreting plasma cells and 
the differentiation of T cells to cytotoxic T lymphocytes 
(CTLs). Anti-adenovirus 5 serotype antibodies have been 
found to target several components of the capsid, includ-
ing hexons and fiber knobs, after both vaccination and 
natural infection to mediate virus neutralization [2, 12]. 
Specifically, the humoral response causes a reduction in 
the viral load hampering the systemic re-administration 
of adenovirus in protocols of gene therapy [11]. While 
neutralizing antibodies (NAbs) prevent re-administration 
of the vector, the antigen-specific T cell response, medi-
ated by CTLs, limits the duration of transgene expression 
and eliminates transduced cells. Therefore, the success 
of long-term gene therapy is dependent on the ability to 
avoid the induction of immune responses against both 
vector and the transgene product [13].
When adenoviruses are directly administrated via the 
circulatory system, 85–98% of the viral dose is accumu-
lated in the liver within 30  min, and the remaining is 
found in lung, kidney, and spleen resulting in off-target 
interactions and systemic toxicity [2, 14]. Moreover, CAR 
is present in most human cell types that contribute to off-
target transduction or non-specific interactions [2, 6].
In humans, in the absence of pre-exiting immunity 
(rare in humans for Ad5 based vectors), the virus may 
bind blood clotting factors [15], IgM [16] and/or erythro-
cytes [17]. All this leads to rapid active RES (Kupffer cell) 
mediated capture and rapid clearance from the blood 
[18]. The sinusoidal endothelial spaces in the human 
liver measure 105 nm [19] i.e. smaller than the diameter 
of a virus with intact fibre domains, providing minimal 
hepatocyte access and infection, hence the minimal liver 
toxicity seen in the clinics compared to mice [20]. This 
is not recapitulated in mice as they do not have CAR on 
their erythrocytes and have a liver sinusoidal endothelial 
gap size of 130–160 nm depending on strain. Hence, RES 
capture but also very high levels of liver infection and 
toxicity are seen in mice.
In humans with pre-existing immunity neutralization 
and RES capture may be even more effective. Unfortu-
nately, this is not recapitulated in research mice because 
they do not have pre-existing immunity, therefore in 
our studies we tried to circumvent this by injecting the 
mice two times with the hAds to simulate pre-existing 
immunity.
The aforementioned limitations have restricted the 
use of hAds for gene therapy to direct intratumoral (IT) 
or organ injection [21]. To overcome these limitations, 
we developed a systemic site-specific delivery system 
where ultrasound (US) contrast agents, here referred as 
microbubbles (MBs), are used as delivery vehicles. These 
hAds, loaded inside shells of acoustically active, lyophi-
lized, lipid-encapsulated, perfluorocarbon filled MBs, are 
released when MBs are destroyed by US at the tumor site. 
These bubbles range between 2.5 and 4.5  µm, and after 
injection into the bloodstream, they can re-circulate 
through the vascular system numerous times for several 
minutes with minimal accumulation and interaction [21–
23]. Their small dimension prevents entrapment within 
the pulmonary capillary bed (~ 5 to 8 µm), yet still ena-
ble proper protection of the viral vectors, such as hAds, 
from the environment [21]. MBs protect the viral pay-
load from detection and rapid degradation by the hosts’ 
immune system allowing for an intravenous (IV) inocula-
tion rather than intratumoral (IT) injection [21, 24]. US 
breaks open the MB/hAds complexes by inducing cavita-
tion, allowing the hAds to transfer their transgene to the 
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sonoporated region. Cavitation of the MBs causes small 
shockwaves, which increase cell permeability by form-
ing temporary micropores on the cell surface, bypass-
ing the receptor-mediated dependence of hAds cellular 
transduction.
In the recent past, we have successfully utilized this 
MB gene transfer system to selectively transfer both 
expression markers and therapeutic genes into tumors 
in immune deficient mice [21, 25–27]. In this study, we 
compared the transduction efficiency of hAd-GFP and 
GFP expression in the mouse prostate cancer cell line 
(TRAMP-C2, C57BL/6 background) and the human 
DU145 prostate cancer cell line. Additionally, using 
healthy immunocompetent C57BL/6 mice or mice bear-
ing a syngeneic TRAMP-C2 prostate tumor, we evaluated 
the capability of ultrasound contrast agents to protect 
systemically-delivered adenoviral vectors from the innate 
and adaptive immune system using an in  vivo model, 
and the contrast agent’s ability to prevent off-target dis-




The DU145 (human prostate adenocarcinoma, radio-
resistant, p53 deficient, derived from a brain metastasis), 
TRAMP-C2 (prostate adenocarcinoma, radio-resist-
ant, wild-type p53, derived from 32-week old TRAMP 
mice) and human kidney embryonic HEK-293 cell lines 
were obtained from the American Type Culture Collec-
tion (ATCC, Rockville, MD). DU145 cells were grown in 
RPMI-1640 (Hyclone, Waltham, MA) supplemented with 
10% fetal bovine serum (FBS) (Hyclone), and 100-units/
ml penicillin supplemented with 1  mg/ml streptomycin 
(Hyclone). TRAMP-C2 cells were grown in Dulbecco’s 
modified Eagle’s medium (Hyclone) supplemented with 
5% FBS (Hyclone), 5% Nu-Serum IV (Corning, Corn-
ing, NY), 5  μg/ml bovine insulin (Sigma Aldrich, St. 
Louis, MO), 10 nM dehydroisoandrosterone 90% (Sigma 
Aldrich), and 100 units/ml penicillin supplemented with 
1  mg/ml streptomycin (Hyclone). The HEK-293 cells 
were grown in Dulbecco’s modified Eagle’s medium 
(Hyclone) supplemented with 10% FBS (Hyclone). All 
cells were grown at 37  °C, in a 5%  CO2 in 95% atmos-
phere incubator.
Adenoviral production
Human adenovirus serotype 5 E1/E3 deleted, which 
expresses the GFP gene under the strong cytomegalovi-
rus (CMV) constitutive promoter, was generated using 
the Ad Easy system (Agilent Technologies, Carlsbad, 
CA) then amplified and purified with the BD Adeno-X 
virus purification kit (BD Biosciences, Mountain View, 
CA) following manufacturer’s directions. Viral titers 
were determined by Tissue Culture Infectious Dose 50 
 (TCID50) and the titer was adjusted to 1 × 1011 plaque-
forming units (PFU)/ml as described. Each viral stock 
was propagated and purified from infected HEK-293 
cells, as previously published [21, 25, 27–29]. HEK-293 
cells were harvested 48  h after infection, pelleted and 
suspended in medium. Cells were lysed by a three-freeze/
thaw cycle method and cell debris were removed by cen-
trifugation. Viruses were purified by chromatography fol-
lowed by dialysis and stored at − 80 °C.
Human adenovirus attachment receptors analysis
DU145 and TRAMP-C2 cells were analyzed for the 
expression of hAd attachment receptors: CAR (coxsackie 
adenovirus receptor), αVβ5 and αVβ3 integrins. Single 
cells suspension was obtained and cells were labeled 
with the following antibodies in cold FACS buffer (PBS 
1× + EDTA 2 mM + FBS 0.5%): Rabbit anti-human CAR 
Monoclonal antibody FITC-conjugated (10799-R271-F, 
Sino Biologicals Inc, Beijing, China), Rabbit Anti-Integ-
rin αV + β5 Polyclonal Antibody Alexa  Fluor® 647 Conju-
gated (bs-1356R-A647, Bioss, Woburn, MA) and Rabbit 
Anti-Integrin αV + β3 (CD51 + CD61) Polyclonal Anti-
body Alexa  Fluor® 488 Conjugated (bs-1310R-A488, 
Bioss). Rabbit Isotype control antibodies were used for 
background normalization. Cells were incubated for 
30 min at 4  °C in the dark, then washed twice in FACS 
buffer. Cells were stained with 2  µg/ml of propidium 
iodide for dead cell exclusion. Samples were acquired 
with a BD Accuri C6 Flow Cytometer (BD Biosciences, 
San Jose, CA) and data analyzed by the CFlow Plus Anal-
ysis Software (BD Biosciences).
Transduction efficiency
Adenoviral transduction efficiency was evaluated 24  h 
post-infection of mouse TRAMP-C2 and human DU145 
cell lines with 10, 25, 50 MOI of hAd-GFP, using DMEM 
media or RPMI-1640 media with 2% heat-inactivated FBS 
(Hyclone), respectively. A qualitative analysis of the trans-
duction efficiency was performed acquiring images of hAd-
GFP infected cells by fluorescence microscopy using an 
inverted Olympus IX70 microscope (Olympus America, 
Inc. Melville, NY). Cells were counterstained with Hoechst 
33342 (Molecular Probes, Eugene, OR). Additionally, the 
percentage of cells positive to GFP was measured 24-h post-
infection of mouse TRAMP-C2 and human DU145 cell 
lines with 10, 25, 50 MOI of hAd-GFP by flow cytometry. 
Propidium iodide labeling was used to exclude dead cells.
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GFP gene expression
Transgene expression was assessed in TRAMP-C2 and 
human DU145 cell lines at 24, 48, and 72  h after infec-
tion with 10 MOI of hAds, using DMEM or RPMI-1640 
media with 2% heat-inactivated FBS (Hyclone), respec-
tively. GFP median fluorescence intensity was measured 
by flow cytometry. Propidium iodide staining was used to 
exclude dead cells.
Preparation of microbubbles
Targeson, (Targeson, Inc. San Diego, CA) uniquely-con-
structed ultrasound contrast agents (perfluorocarbon 
microbubbles, encapsulated by a lipid monolayer and 
polyethylene glycol stabilizer), were prepared following 
manufacturer’s instructions. MBs were reconstituted in 
the presence or absence of 1 ml of 1 × 1011 plaque-form-
ing units/ml of Ads and unenclosed, surface-associated 
Ads were inactivated, as previously described [21, 25, 27].
Briefly, unenclosed and free adenoviruses were inac-
tivated by incubating 1 volume of microbubbles formed 
in the presence of Ad-GFP with 10 volumes of a solu-
tion containing 60 mg/ml of human complement (Sigma 
Aldrich, Saint Louis, MS) for 30 min at 37 °C. Microbub-
bles were then washed with 10  ml of phosphate buffer 
saline solution (PBS). The milky white suspension float-
ing on the top of PBS was then collected and used in the 
in vitro and in vivo experiments. We delivered  109 PFU 
Ad-GFP/mouse using the MBs/US system, and the titer 
was comparable to the one injected in the control mice 
(IV and IT injections) (see Additional file 1).
In vivo ultrasound‑targeted microbubble destruction
Animal studies were performed in accordance with 
National Institutes of Health recommendations and the 
approval of the Institutional Animal Care and Use Com-
mittee. Animal care and humane use and treatment 
of mice were in strict compliance with (i) institutional 
guidelines, (ii) the Guide for the Care and Use of Labora-
tory Animals (National Academy of Sciences, Washing-
ton, DC, 1996), and (iii) the Association for Assessment 
and Accreditation of Laboratory Animal Care Interna-
tional (Rockville, MD, 1997). All the animals used in 
these studies were 8–11  week-old male C57BL/6  (H2b) 
immunocompetent mice (Jackson Laboratories, Bar 
Harbor, ME). Two in  vivo experiments were performed 
using a total of 30 mice divided into groups containing 
3–6 mice for each experiment. The first experiment was 
performed in healthy C57BL/6 mice while the second uti-
lized C57BL/6 bearing a syngeneic TRAMP-C2 tumor. To 
establish syngeneic tumor grafts, the mice were injected 
in the right flank with TRAMP-C2 prostate adenocar-
cinoma cell lines (5 × 106 cancer cells) using a 20-gauge 
needle. Treatment was started when the tumor reached 
50–100 mm3 of volume. During the experimental proce-
dure, the mice were sedated using an IMPAQ6 anesthe-
sia apparatus (VetEquip, Pleasanton, CA) saturated with 
3–5% isofluorane and 10–15% oxygen with the aid of a 
precision vaporizer (VetEquip), and placed on a warming 
mat set at 37 °C. Treatments were delivered intravenously 
(IV) or intratumorally (IT) in a volume of 100  μl using 
a 30-gauge needle. US exposure was performed with a 
Micro-Maxx SonoSite ultrasound machine (SonoSite) 
equipped with the transducer L25 set at 0.7 Mechanical 
Index (MI), 1.8 MPa for 10 min [21, 25, 27].
TNF‑α and IL‑6 quantification
Two hours after the first IV or IT injection, mice were 
deeply sedated and 100  μl of blood was collected by 
puncture of the mandibular vein using a Goldenrod Ani-
mal Lancet (Braintree Scientific, Inc., Braintree, MA). 
Mouse serum TNF-α and IL-6 levels were analyzed using 
Quantikine HS Mouse TNF-alpha (R&D System, Min-
neapolis, MN) and Quantikine Mouse IL-6 and (R&D 
System) Immunoassay solid-phase ELISAs, following 
manufacturer’s directions.
Anti‑adenovirus antibodies detection
At the experimental endpoints, mice were deeply anes-
thetized, and blood was collected from the heart. After-
wards, the mice were sacrificed by  CO2 gas and cervical 
dislocation.
ELISA plates were coated overnight at 4  °C with 
5 × 106 vp/well of Ad-GFP. Plates were blocked for 2 h at 
room temperature with 3% BSA/PBS. Mice serum was 
heat inactivated at 56  °C for 30  min, diluted 1:3000 in 
1%BSA/0.05%Tween20/PBS, added to the wells in trip-
licate and incubated for 2 h at room temperature. Reac-
tive antibodies were detected using a secondary antibody 
sheep anti-mouse IgG HRP-conjugated (NA931, GE 
Healthcare, Chicago, IL). SureBlue TMB Peroxidase Sub-
strate (KPL, Gaithersburg, MD) was added to each well 
and color development was assessed at 650  nm using a 
microplate reader.
INF‑γ ELISPOT
Immediately following mice euthanasia, spleens were 
collected and processed. Red blood cells were removed 
using a Red Blood Cells Lysis buffer (Affymetrix, Santa 
Clara, CA). Splenocytes were suspended at 2 × 106 cells/
ml in AIM V medium containing l-glutamine, strepto-
mycin sulfate 50 µg/ml, and gentamicin sulfate 10 µg/ml, 
and supplemented with 50 µM 2-mercaptoethanol. Two 
hundred-thousand cells/well were stimulated with 2 µg/
ml of DNA-binding protein peptide, corresponding to 
 DBP418–426 (FASLNAEDL, H-2Db restricted peptide, New 
England Peptide, Gardner, MA) [30] for 24 h. Stimulation 
Page 5 of 14De Carlo et al. J Transl Med           (2019) 17:19 
of splenocytes with 0.05  µg/ml of anti-mouse CD3 was 
used as positive control (552774, BD Biosciences, Frank-
lin Lakes, NJ). Splenocytes were subjected to ELIS-
pot assay using the INF-γ ELISpot PLUS kit (Mabtech, 
Nacka Strand, Sweden) following manufacturer’s direc-
tions. Spots, corresponding to INF-γ secreting cells, were 
counted using a Zeiss ELISpot reader system (service 
provided by ZellNet, Inc. Fort Lee, NJ).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
6 statistical software (Graphpad, Inc., La Jolla, CA). One 
and two-way analysis of variance (ANOVA) with Tukey 
or Bonferroni multiple comparisons post-test was used 
to determine the statistical significance of the differences 
between experimental groups. Multiple t-test was used 
for the ELISpot analysis. p-values of less than 0.05 were 
considered statistically significant.
Results
TRAMP‑C2 and DU145 cells express hAd receptors 
integrins αVβ5, αVβ3, and CAR 
The expression profile of surface proteins known to be 
responsible for the specific attachment of hAd5 to human 
cells was evaluated by flow cytometry (Fig.  1a, b). Both 
human DU145 and mouse TRAMP-C2 prostate cancer 
cells were positive to the expression of integrin αVβ5 and 
αVβ3. The percentage of cells expressing human Cox-
sackie and Adenovirus Receptor (CAR), as expected, was 
higher in the human cell line DU145 when compared to 
the mouse TRAMP C2 cells (97 ± 0.9% vs. 62.9 ± 1.5%).
Fig. 1 Human adenoviral receptors expression in TRAMP-C2 and DU145. a TRAMP-C2 and DU145 cells were labeled with Rabbit Anti-human 
Coxsackie adenovirus receptor FITC conjugated (hCAR), Rabbit Anti-Integrin αV + β5 Alexa  Fluor® 647 Conjugated and Rabbit Anti-Integrin αV + β3 
Alexa  Fluor® 488 Conjugated. Percentages are represented as mean ± SEM of three biological repetitions. b Representative flow cytometer 
histograms showing the percentage of cells that are expressing human adenovirus receptors. Black: negative control, Red: isotype control, Blue: 
specific antibody
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TRAMP‑C2 and DU145 cells are transduced by hAd‑GFP
Despite the high host specificity of adenovirus, we 
wanted to define if murine cells could be infected by a 
hAd. The transduction efficiency of murine TRAMP-C2 
and human DU145 prostate cancer cell lines by hAd-
GFP was assessed 24  h post infection with 10, 25, and 
50 MOI (multiplicity of infection) of hAd-GFP. Using 
fluorescence microscopy, we observed a dose-dependent 
increase of GFP positive cells in both TRAMP-C2 and 
DU145 cells (Fig. 2a). DU145 cells exhibited a higher level 
of transduction in comparison to TRAMP-C2 cells at 
each multiplicity of infection.
To quantify TRAMP-C2 and DU145 cells transduc-
tion with hAd-GFP at 10, 25, and 50 MOI, a flow cytom-
etry analysis was performed 24 h post infection (Fig. 2b). 
An increase in the percentage of GFP positive cells was 
observed in both TRAMP-C2 and DU145 cells as the 
MOI was increased. However, when comparing similar 
treatments, TRAMP-C2 cells were significantly less 
affected than were DU145 as indicated by a GFP positive 
population of only 17.7 ± 2.8% at 50 MOI in TRAMP-C2 
vs 59 ± 1.5% in DU145.
TRAMP‑C2 and DU145 cells express GFP 
following transduction with hAd‑GFP
The hAds-GFP used in this study express the GFP gene 
under the strong (CMV) cytomegalovirus constitutive 
promoter. In order to assess if mouse TRAMP-C2 and 
human DU145 prostate cancer cells were able to express 
GFP after transduction with hAd-GFP, both cell lines 
were infected with 10 MOI of hAds, and the median 
fluorescence intensity (MFI) was measured at 24, 48, and 
72  h to determine the degree of GFP protein synthesis. 
We showed that the GFP transgene is expressed in both 
TRAMP-C2 (Fig.  3a) and DU145 (Fig.  3b) cell lines. 
When comparing human and murine cell lines, GFP 
Fig. 2 Human adenoviral transduction efficiency in TRAMP-C2 and DU145. a TRAMP-C2 and DU145 cells were transduced with 10, 25, 50 MOI of 
hAd-GFP for 24 h and images were acquired by fluorescence microscopy. Nuclei were counterstained with Hoechst 3334. b TRAMP-C2 and DU145 
cells were transduced with 10, 25, 50 MOI of hAd-GFP for 24 h and the percentage of cells transduced were determined by flow cytometry. Data are 
representative of three biological repeats, analyzed by two way ANOVA, Bonferroni’s post-test ***p < 0.001
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MFI in DU145 was higher than TRAMP-C2 at all 3 times 
points corresponding to a greater transduction efficiency 
of hAds in human cells. However, when GFP MFI was 
corrected by the percentage of  GFP+ cells detected at 24, 
48 and 72 h, a similar GFP expression in both murine and 
human cells was observed (Fig. 3c).
Microbubbles protect hAd‑GFP from activation 
of the innate immune system
The first barrier to viral infection is the innate immunity, 
which is comprised of cellular and soluble components 
including complement, immunoglobulin, erythrocyte 
and clotting factor binding (depending on species), and 
inflammatory cytokines (TNF-α, IL-1β, IL-6) [13]. To 
evaluate the MBs’ ability to protect in immune competent 
animals the hAds from the innate immunity, the levels of 
serum inflammatory cytokines after IV and IT injection 
of both unprotected hAd-GFP and MB-protected hAd-
GFP were measured using immunoassay solid-phase 
ELISAs. The experimental design is shown in Fig.  4. 
Direct IV injection of unprotected hAd-GFP in healthy 
C57BL/6 immunocompetent mice (Fig.  4a, EXP.1) 
induces a marked increase in both TNF-α (Fig.  5a) and 
IL-6 (Fig.  5b) in comparison to control groups (saline 
and MBs only). As anticipated, the administration of 
MB-protected hAd-GFP completely shielded the adeno-
virus, preventing the activation of innate immunity in 
both ultrasound-treated and non-treated groups. When 
C57BL/6 mice bearing a syngeneic tumor were used 
(Fig. 4b, EXP.2), we detected an increase in both TNF-α 
(Fig. 5c) and IL-6 (Fig. 5d) in hAd-GFP IV injected mice 
just as we did using C57BL/6 mice without tumor; how-
ever, the increase in IL-6 using hAd-GFP IV injected mice 
was less substantial than that of the C57BL/6 mice with-
out tumor. When C57BL/6 mice bearing tumors received 
an IT injection, the level of TNF-α was again compara-
ble to the hAd-GFP IV group, but IL-6 production was 
absent. As expected, we observed that the administration 
of hAd-GFP/MBs complexes allows for the evasion of 
adenovirus from the innate immunity with or without the 
use of ultrasound.
Microbubbles protect hAd‑GFP from the activation 
of the humoral response
The production of neutralizing antibodies specific for 
hAd-GFP (IgG anti-hAd) was evaluated using a direct 
ELISA assay. Blood was collected from the heart at the 
experimental endpoints of 2  months in C57BL/6 mice 
(Fig.  4a, EXP.1) and 1  month in C57BL/6 mice bear-
ing a syngeneic tumor (Fig. 4b, EXP.2). There was a sta-
tistically higher titer of IgG anti-hAd when mice were 
injected intravenously with unprotected hAd-GFP. The 
production levels of neutralizing antibodies specific for 
hAd-GFP nearly doubled when mice received two IV 
injections of unprotected hAd-GFP in EXP.1 (Fig.  6a). 
C57BL/6 mice from EXP.2 (Fig.  6b) that received an IT 
injection of hAd-GFP showed a lower increase in NAbs 
when compared to the IV injection groups. Not sur-
prisingly, we observed that the administration of MBs/
Fig. 3 GFP protein expression in TRAMP-C2 and DU145. a TRAMP-C2 
and b DU145 cells were transduced with 10 MOI of hAd-GFP and the 
median fluoresce intensity of GFP transgene (GFP MFI) was analyzed 
by flow cytometry at 24, 48 and 72 h post transduction. c GFP MFI 
was corrected by the percentage of GFP positive (GFP+) cells to 
compare GFP expression in equal number of transduced cells. Data 
are representative of three biological repeats analyzed by (a, b) 
one way ANOVA, Tukey’s post-test +p<0.05, ++p < 0.01; c two ways 
ANOVA, Bonferroni’s post-test, *p < 0.05, **p < 0.01
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hAd-GFP complexes ± US completely prevented the 
activation of a humoral response in immune competent 
mice.
Microbubbles protect hAd‑GFP from the activation 
of the cellular response
The presence of antigen-specific INF-γ producing  CD8+ 
T cells was assessed by stimulating the splenocytes 
ex  vivo with  DBP418–426 peptide. The number of cells 
responding to the stimulation was evaluated using an 
ELISpot assay. Splenocytes were collected at the experi-
mental endpoints. A statistically higher amount of INF-γ 
spot forming units were found in the stimulated spleno-
cytes compared to the un-stimulated splenocytes in the 
IV-injected, unprotected hAd-GFP mice. The number of 
INF-γ spot forming units counted in samples from mice 
in EXP.1 (Fig.  7a, c) that received two IV injections of 
unprotected hAd-GFP was almost twofold of that which 
was observed in the mice from EXP.2 (Fig.  7b, d). Mice 
from EXP.2 (Fig.  7b) that received an IT injection of 
hAd-GFP showed a greater number of INF-γ spot form-
ing units when compared to the IV injections. Notably, 
we did not observe a statistically significant activation 
of splenocytes after stimulation with  DBP418–426 in mice 
that received MBs/hAd-GFP complexes ± US treatment 
indicating that the UMTD we developed prevented the 
activation of a humoral response in immune competent 
mice.
Fig. 4 In vivo experimental design. Two in vivo experiments were performed. a In experiment 1 we used healthy C57BL/6. Mice were injected IV 
with either saline, MBs, hAd-GFP, MBs(hAd-GFP), or MBs(hAd-GFP) + US. Blood samples were collected 2 h post-injection to determine inflammatory 
cytokine response. After 4 weeks, mice were re-injected and 4 weeks later, mice were sacrificed and blood and organs were collected. b In 
experiment 2 we used C57BL/6 mice injected subcutaneously with 5 × 106 TRAMP-C2 cells. When syngeneic tumor grafts were established 
(approximately 3 weeks post-injection of cancer cells, and with tumor volumes between 50 and 100 mm3) mice were injected IV with either 
saline, MBs, hAd-GFP, MBs(hAd-GFP), MBs(hAd-GFP) + US, or via IT with hAd-GFP. Two hours after the treatment, blood samples were collected to 
determine inflammatory cytokine response. At the endpoint of 4 weeks, mice were sacrificed and blood and organs were collected. Activation of 
the innate and adaptive immune response were evaluated in both experiments by ELISA (TNF-α, IL-6 and NAbs)
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Discussion
Prostate cancer is a very common cancer in men in the 
United States ranking as the third-leading cause of can-
cer death in men [31]. Primary prostate cancer can be 
treated successfully in many cases with surgical prostate 
resection, radiation, and hormonal therapy, with radia-
tion therapy being used as the main choice for locally 
advanced prostate cancer. However despite receiving 
treatment, over a third of these patients will progress 
to an androgen-independent, radiation-resistant pros-
tate cancer [32]. There is a need to develop more effec-
tive therapeutic approaches, and gene therapy represents 
a promising new treatment option. Therapeutic genes 
of choice include pro-apoptotic genes, tumor suppres-
sor genes, antisense sequences for oncogenes, and anti-
tumor DNA vaccines. Recent gene therapy clinical trials 
for prostate cancer have used Adenovirus as a highly 
efficient gene transducing tool [24]. Together with the 
Adeno-associated virus, adenoviral vectors belong to the 
category of the non-integrating vectors, they can be pro-
duced at a higher titer and display a robust expression of 
the therapeutic genes. These vectors can be easily engi-
neered to make them safer and less immunogenic [33]. 
For example, the substitution of serotype 5 hexons with 
serotype 3 can protect adenovirus form inactivation by 
neutralizing antibody anti-hAd5 that are commonly cir-
culating in patients due to preexisting immunization [34, 
35]. In fact, the main challenges associated with the sys-
temic delivery of adenoviral vector are not only the naïve 
immune response but also the immunity to the virus 
serotype stemming from natural infection and liver toxic-
ity [13].
Adenoviruses interact with the host cell and internalize 
using specific receptors. Adenovirus 5 is one of the main 
serotypes currently used in the clinics, and it employs 
Fig. 5 Quantification of serum inflammatory cytokines. Innate immunity was evaluated by sandwich ELISA by quantifying serum cytokines TNF 
alpha a EXP.1, and c EXP.2, and serum IL-6 b EXP.1, and d EXP.2. Groups means are represented as horizontal bars (EXP.1 n = 6 mice/group; XPp.2 
n = 4 mice for saline IV, MBs IV, hAd-GFP IV, MBs(hAd-GFP) IV groups and n = 3 mice for MBs(hAd-GFP) + US IV and hAd-GFP IT. Data are analyzed by 
two way ANOVA and Tukey’s post-test, *p < 0.05, ***p < 0.001)
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Coxsackie and Adenovirus Receptor (CAR) to adhere to 
target cells [36]. This receptor is expressed at low levels 
in primary tumors, including prostate cancer, when com-
pared to established human cancer cell lines [37].
Infection and replication by human adenovirus has 
been thought to be restricted to human cells. Murine 
cells have been generally considered non-permissive, 
thereby limiting preclinical studies of gene transfer tech-
niques [38]. However, here we showed that murine tissue 
could be transduced with hAds even if at a lower extent.
To overcome the aforementioned challenges through 
elicitation of the immune response and off-target viral 
distribution and expression, we have developed an image-
guided gene transfer method (US Patent 8,454,937) 
Fig. 6 Detection of serum neutralizing antibodies. Humoral response was determined by direct ELISA of serum NAbs (IgG anti-hAd), a Exp.1, b 
Exp.2. Group’s means are represented as horizontal bars. (EXP.1 n = 6 mice/group; EXP.2 n = 4 mice for saline IV, MBs IV, hAd-GFP IV, MBs (hAd-GFP) IV 
groups and n = 3 mice for MBs(hAd-GFP) + US IV and hAd-GFP IT. Data are analyzed by two way ANOVA and Tukey’s post-test, *p < 0.05, **p < 0.01, 
***p < 0.001)
Fig. 7 Detection of INF-γ producing  CD8+ T. Cellular response was assay by ELIspot counting the number of INF-γ spots forming units after ex vivo 
stimulation of splenocytes with  DBP418–426 peptide a, c EXP.1, b, d EXP.2. Group means are represented as in the histograms. c, d Exemplary samples. 
The nonspecific activator anti-CD3 antibody was used as positive control for the assay. (EXP.1 and EXP.2 n = 3 mice/group. Data are analyzed by 
multiple t-test of splenocytes from control and treated mice stimulated with media, spontaneous, or  DBP418–426, stimulated, *p < 0.05, ***p < 0.001)
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utilizing a combination of lipid-encapsulated perfluoro-
carbon microbubbles (MBs) and ultrasonic waves (US) 
to enclose and protect hAds from the immune system to 
deliver the adenoviruses to a site-specific tissue bypass-
ing the requirement of specific receptors [21, 25–27]. 
We have previously shown in immune compromised 
mice that this innovative gene transfer system can be 
used to specifically deliver hAd-GFP to a prostate tumor 
xenograft after systemic injection of the virus [25]. We 
demonstrated, by delivering a replication-deficient or a 
conditionally replication-competent adenovirus express-
ing the pro-apoptotic gene mda7/interleukin-24 enclosed 
in microbubble and in combination with ultrasound, that 
we could achieve sustained expression of the transgene in 
the sonoporated region and induce a reduction or com-
plete eradication of a human prostate tumor xenograft 
[21]. Using this microbubble gene transfer method we 
were also able to radio-sensitize and reduce the tumor 
burden of a tumor xenograft of the prostate cell line 
DU145 by delivering replication-deficient human adeno-
virus expressing the tumor suppressor genes p53, and 
pRb [27]. Moreover, we confirmed our previously pub-
lished data, showing that after reconstitution of micro-
bubbles in the presence of adenovirus, the microbubbles 
need to be treated with human complement in order to 
inactivate any adenovirus loosely attached or included 
within the lipid shell and to achieve specific delivery of 
the hAds. The complement-treated microbubble-encap-
sulated adenovirus can be systemically injected intra-
venously into an immunocompetent C57BL/6 mouse 
without eliciting any innate immune response when 
compared to non-treated microbubbles or not protected 
adenovirus [24, 25].
The validity of our established image-guided gene 
therapy method has been confirmed by an independent 
laboratory that is using ultrasound-targeted microbub-
ble (MB)-destruction to deliver conditionally replication-
competent oncolytic adenoviruses that simultaneously 
produce a systemically active cancer-specific therapeutic 
cytokine [39] in prostate cancer.
The aim of the present study was to test if the micro-
bubble/US system we have established [21, 24, 25, 27] 
could efficiently deliver human adenoviruses to a targeted 
diseased tissue protecting the virus from the innate and 
adaptive immunity using immunocompetent TRAMP-
C2 mice (C57BL/6 background) as pre-clinical prostate 
cancer model.
Using an in  vitro model, we compared the transduc-
tion efficiency of the hAd-GFP in the mouse TRAMP-C2 
and human DU145 prostate cancer cell lines and found 
that the pattern of expression of the CAR receptors and 
integrins αVβ5 and αVβ3, all required for the adhesion 
and internalization of the adenovirus by the host cells, 
was comparable. However, notwithstanding this similar-
ity, we observed a pronounced reduction in the uptake of 
the virus when comparing murine cells and human pros-
tate cell line. This can be explained by the high sequence 
homology in the extracellular domain of CAR from 
human and mice [40, 41] and CAR-independent path-
ways for cell transduction [42]. However, we detected a 
dose-dependent increase of the GFP positive cells in both 
cell lines 24 h post-infection. Finally, and more relevant 
for the general purpose of our study, we showed that both 
mouse TRAMP-C2 and human DU145 prostate cancer 
cell lines were able to support an efficient expression of 
the GFP transgene regulated by the strong CMV pro-
moter at 48 and 72 h post-transfection.
The second goal of this study was to test the ability of 
the microbubbles to protect the systemically delivered 
adenoviral vectors from the innate and adaptive immune 
system of an immunocompetent mouse in vivo, using our 
image-guided delivery system. For this purpose, we used 
the TRAMP-C2 model of prostate cancer. From the orig-
inal TRAMP mouse, that spontaneously develops pros-
tate cancer, several cell lines have been established, such 
as TRAMP-C1 and C2, and these can be used to establish 
syngeneic subcutaneous grafts in C57BL/6 mice [43]. In 
our study, we used healthy immunocompetent C57BL/6 
mice and mice bearing a syngeneic TRAMP-C2 prostate 
tumor to better represent the immune response of cancer 
patients.
Adenoviruses are able to induce a strong inflammatory 
response, which at its first step involves the activation of 
NK, professional APC, neutrophils, the complement cas-
cade and the secretion of cytokines [13]. Dendritic cells in 
the spleen have been demonstrated to be directly trans-
duced by systemically administered adenovirus result-
ing in the induction of IL-6, IL-12, and other cytokines 
[44]. The administration of human adenoviral vectors 
in protocols of gene therapy can lead to side effects in 
patients such as liver toxicity, thrombocytopenia and 
acute inflammation [45]. In order to assess if the micro-
bubbles could protect the hAds from the activation of the 
innate immunity following systemic delivery, we injected 
the hAds enclosed in microbubbles through the tail vein 
of the mice. Two hours after intravenous injection, cor-
responding to the previously reported median time of 
secretion peak for TNF-α and IL-6 in C57BL/6 mice [46–
48], blood samples were collected from the treated mice 
and levels of cytokines in their serum were quantified. 
We observed that the microbubbles completely protected 
hAds from eliciting an immune response, as showed 
by the absence of inflammatory cytokines when com-
pared to the expected and well-documented response 
obtained after injection of non-protected hAds [11, 13, 
44, 49, 50]. We did not observe any difference among 
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ultrasound-treated and non-treated mice (EXP.1 to the 
right kidney, EXP.2 to the tumor on the right flank), con-
firming the high stability of the microbubbles used. Fur-
thermore, we noticed a very low level or absence of virus 
leak when bubbles cavitation was induced by sonopo-
ration. Mice that received an intratumoral injection of 
the hAds showed an increase of only TNF-α expression, 
which naturally precedes IL-6 [46, 48], suggesting that 
anatomical barriers such as the tight junction between 
tumor cells may have reduced the path of the viral vector 
delaying the elicitation of innate immunity.
The second barrier to viral infection is the adaptive 
immunity, which is comprised of activated  CD4+,  CD8+ 
T cells and antibody-secreting plasma cells [13]. During 
a scheduled treatment of cancer gene therapy, the real 
obstacle to effectively repeating systemic administra-
tions of replication-deficient adenoviral vectors is the 
inactivation of the virus by complement proteins, pre-
existing anti-viral and neutralizing antibodies that can 
reduce the efficiency of transfection [11, 13]. In order 
to assess the activation of the adaptive immunity, at the 
experimental end point of 1  month from the last injec-
tion of microbubble encapsulated hAds either in combi-
nation with US or not, we measured the levels of serum 
IgG anti-adenovirus. We observed that the microbubbles 
completely protected hAds injected intravenously from 
eliciting a humoral response as shown by the absence 
of a statistically significant increase in secretion of anti-
hAds antibodies. We could not detect differences among 
mice that received ultrasound treatment or not, confirm-
ing once again our previous observations. On the other 
hand, we detected a robust production of neutralizing 
antibodies in mice injected intravenously with unpro-
tected hAds as observed by others [11, 13]. Additionally, 
in mice injected intravenously with unprotected hAds, 
the relative number of neutralizing antibodies detected 
was twice as much in EXP.1 compared to EXP.2 due to 
the treatment schedule. Instead, intratumoral injection of 
hAds induced a lower titer of neutralizing antibody prob-
ably due to the target tissue characteristics and the route 
of administration.
To assess the activation of cell-mediated immunity, we 
investigated the incidence of antigen specific INF-γ pro-
ducing  CD8+ T cells. The vector we used in our experi-
ments is a 1st generation, E1 deleted adenovirus that 
still allows for the leaky late gene expression of some 
viral products including the nonstructural DNA Binding 
Protein (DBP). DBP contains a MHC-class I restricted 
epitope that have been shown to be a  CD8+ principal 
epitope in C57BL/6 mice [30]. In order to detect the pres-
ence of DBP specific INF-γ producing  CD8+ T cells, we 
performed an INF-γ ELIspot assay. We collected spleno-
cytes at the experimental end points and stimulated them 
ex  vivo with the DBP peptide and INF-γ spot forming 
units were counted. We observed that the systemic injec-
tion of microbubble encapsulated hAd-GFP with or with-
out the use of US treatment does not induce a statistically 
significant increase in the number of spots observed 
when compared to the spontaneous release of INF-γ in 
both healthy mice (EXP.1) and mice bearing a prostate 
tumor (EXP.2). Conversely, we observed a strong activa-
tion of  CD8+ T cells in the positive controls (IV and IT 
injections of naked hAds) and the highest count of INF-γ 
spot forming units was detected after intratumoral injec-
tion of hAd-GFP confirming that the route of administra-
tion and viral dose administered may affect the type of 
immune response [30, 51, 52].
Conclusions
These results demonstrated that our MBs/US-guided 
gene delivery system can effectively protect a viral vector 
from the activation of both humoral and cellular immu-
nity response. Also, our data provides evidence that the 
TRAMP-C2 mouse model of prostate cancer is a suitable 
system to study the feasibility of this novel image-guided 
gene transfer technique in immune competent animals 
offering the milestone and opportunity to further trans-
late this ultrasound-mediated MBs/hAd delivery system 
from the bench to the bedside.
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Additional file 1: Figure S1. Virus Titration. Virus stocks used for the in 
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receiving MBs(Ad-GFP) were treated with US for 1 minute. 24 hours after 
infection, the percentage of cells transduced were determined by Flow 
Cytometry. Data are representative of three biological repeats, analyzed by 
Student T-test (Ad-GFP vs. MBs(Ad-GFP)+US). *p < 0.05, **p < 0.001.
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